Abstract
Tyrosine kinase 2 (TYK2) is involved in type I interferon (IFN-I) signaling through IFN receptor 1 (IFNAR1). This signaling pathway is crucial in the early antiviral response and remains incompletely understood on B cells. Therefore, to understand the role of TYK2 in B cells, we studied these cells under homeostatic conditions and following in vitro activation using Tyk2-deficient (Tyk2−/−) mice. Splenic B cell subpopulations were altered in Tyk2−/− compared to wild type (WT) mice. Marginal zone (MZ) cells were decreased and aged B cells (ABC) were increased, whereas follicular (FO) cells remained unchanged. Likewise, there was an imbalance in transitional B cells in juvenile Tyk2−/− mice. RNA sequencing analysis of adult MZ and FO cells isolated from Tyk2−/− and WT mice in homeostasis revealed altered expression of IFN-I and Toll-like receptor 7 (TLR7) signaling pathway genes. Flow cytometry assays corroborated a lower expression of TLR7 in MZ B cells from Tyk2−/− mice. Splenic B cell cultures showed reduced proliferation and differentiation responses after activation with TLR7 ligands in Tyk2−/− compared to WT mice, with a similar response to lipopolysaccharide (LPS) or anti-CD40 + IL-4. IgM, IgG, IL-10 and IL-6 secretion was also decreased in Tyk2−/− B cell cultures. This reduced response of the TLR7 pathway in Tyk2−/− mice was partially restored by IFNα addition. In conclusion, there is a crosstalk between TYK2 and TLR7 mediated by an IFN-I feedback loop, which contributes to the establishment of MZ B cells and to B cell proliferation and differentiation.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00018-024-05234-y.
Keywords: Tyrosine kinase 2 (TYK2), TYK2-deficient mice, Aged B cells, Marginal zone B cells, Follicular B cells, Toll-like receptor 7 (TLR7), Type I IFN, IFNα, β receptor
Introduction
B lymphocytes are an essential component of the humoral immune response. They have a diverse origin: adult B-1 cells arise almost entirely from fetal precursors, while B-2 cells derive from B cell progenitors in the bone marrow [1]. B-2 cells migrate from the bone marrow as immature cells, and they colonize the spleen and lymph nodes as newly formed or transitional B cells. Afterward, they differentiate into follicular (FO) and marginal zone (MZ) B cells [2] and, in aged and autoimmune prone mice, into the so-called aged B cells (ABC) [3]. FO B cells enter the germinal center to participate in T cell-dependent immune reactions, undergoing class switching and somatic hypermutation to produce high-affinity antibodies and memory B cells [4]. MZ B cells are the first line of defense against blood-borne pathogens and rapidly produce low-affinity IgM antibodies against encapsulated bacterial and polysaccharide antigens, independently of T cells [5, 6]. In addition to B cell receptor (BCR), B cell subpopulations express other receptors such as Toll-like Receptors (TLRs) that modulate their ability to respond to pathogen antigenic patterns [7–9].
Janus kinases (JAKs) are a family of non-receptor tyrosine-kinase proteins with four members (TYK2, JAK1-3) that are associated with cytokine and growth factor receptors [10]. TYK2 was initially identified as essential for IFNα signaling through the IFNα/β receptor alpha chain (IFNAR1), while JAK1 was associated with the IFNAR beta chain (IFNAR2) [11, 12]. IFNAR engagement results in JAK1 and TYK2 activation leading to the formation of the transcription factor complex IFN-stimulated gene factor 3 (ISGF3), which is composed of signal transducers and activators of transcription (STAT1 and STAT2) and IFN-regulatory factor 9 (IRF9) [13]. This complex translocates to the nucleus to promote transcription of IFN-stimulated genes [12, 14], whose products establish an antiviral state in the cell [15, 16]. Type I IFNs exert antiproliferative and immunomodulatory effects essential to control viral infection. In addition, TYK2 signals through several cytokine receptors as IL-12Rβ1, IL-10Rβ, IL-6Rα, IL-11Rα, CNTFRα and IL-13Rα1 [17]. The impairment of JAK/STAT signaling has been related with susceptibility to infection, autoimmune diseases and deregulated leukocyte proliferation and survival [18].
Patients with TYK2 deficiency have defects in the signaling of the above mentioned cytokines leading to a high susceptibility to intracellular viral and bacterial infections [19–23]. In contrast, TYK2 overexpression has been described in lung leukocytes obtained from SARS-CoV-2 infected patients, where is directly related to high rates of vital risk [24]. Protective TYK2 genetic variants have been identified in autoimmune diseases [25, 26], but their relevance in other pathologies such as hematopoietic malignancies is still uncertain [27]. Consistent with the human data, TYK2-deficient (Tyk2−/−) mice exhibit defective IL-12, IL-23 and type I IFN signaling leading to a down-regulation of Th1 and Th17 cell subpopulations and to susceptibility to viruses and encapsulated bacteria [28–31]. In addition, Tyk2−/− mice exhibit reduced inflammatory responses in several autoimmune disease models [26, 32–34] and are resistant to LPS-induced septic shock [35]. This resistance was thought to be mediated primarily by a suppression of the IFNβ-dependent pathway. Yet, TYK2 has been described as an upstream regulator of CASP11-induced pyroptosis, which is required for LPS-induced lethality in mice [36]. Furthermore, an inhibition of IL-27 and an increase in IL-10 production in Tyk2−/− peritoneal macrophages have been linked to the anti-inflammatory and immunosuppressive phenotype induced by TYK2 deficiency [37, 38].
The way in which TYK2 deficiency affects T cell-dependent B cell differentiation from naive B cells to plasma and memory cells has been studied with T helper follicular cells and splenic B cells derived from patients with monogenic TYK2 mutations [39]. The effect of TYK2 on IL-7-dependent B cell lymphopoiesis, apoptotic responses to IFN-I and mitochondrial respiration maintenance in bone marrow-derived pro-B lymphocytes has been described in mice [40–42], whereas the role of this tyrosine kinase in T cell independent B cell responses remains incompletely understood. Therefore, herein we characterized the B cell subpopulations in immune organs of Tyk2−/− mice. We found that under homeostatic conditions the total number of B cells was not altered. However, the splenic B cell distribution showed an increase of ABC and a decrease of MZ cells, while FO cells remained unchanged. Differentially expressed gene (DEG) analysis of isolated MZ and FO cells from Tyk2−/− compared to WT mice in homeostasis shared an inhibited type I IFN-dependent pathway, which linked TYK2 deficiency with TLR7 down-regulation. Accordingly, in vitro stimulation of Tyk2−/− splenic B cells with TLR7 ligands (TLR7L) demonstrated a defect in proliferation and differentiation, while their response to TLR4 ligands or anti-CD40 + IL-4 was comparable to that of WT B cells. Furthermore, in vitro TLR7L-stimulated Tyk2−/− splenic B cells showed a diminished humoral response. Taking these results together, we propose that impaired signal transduction through TLR7 in Tyk2−/− mice affects splenic B cells, in particular the establishment and differentiation of MZ cells, and contributes to immunosuppression.
Material and methods
Mice
Three to four-month-old male and female C57BL/6N (WT) and B6N.129P2-Tyk2KO tm1Biat (Tyk2−/−) mice (on a C57BL/6N background) [28] (kindly provided by Dr. M. Müller, Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria) were bred and maintained in the animal facilities at the School of Medicine of the Universidad Autónoma de Madrid. All experiments were performed in accordance with the National RD 53/2013 and European Union 2010/63/EU directive and under the EU and National Animal Care guidelines. All protocols were approved by Consejería de Medio Ambiente de la Comunidad de Madrid (PROEX 353.8/21).
Flow cytometry and sorting
Cell pellets were obtained from spleen, peripheral blood mononuclear cells (PBMCs), axillary and inguinal lymph nodes, bone marrow (femur and tibia), thymus, Peyer’s patches or peritoneal washed cells. Cell homogenates from the spleen were treated with ACK lysing buffer (Gibco™, Thermo Fisher Scientific, Waltham, MA, USA) to lyse the erythrocytes. In the case of PBMCs, a density gradient (Lymphoprep™, Cedarlane Laboratories, Burlington, ON, Canada) was performed. The cells were then suspended in staining buffer (2.5% Fetal Calf’s Serum) in Dulbecco’s Phosphate buffered saline (DPBS, BioWhittaker™, Lonza Group, Basel, Switzerland). Non-specific antibody binding was blocked by incubation with anti-Fc-Block (clone 2.4G2: BD Biosciences, San Jose, CA, USA). The single cell suspensions were stained with the specific mAbs listed in Table S1 and analyzed by flow cytometry. For intracellular staining, after Fc-blocking and surface and live/dead staining (LIVE/DEAD™ kit, Invitrogen™, Thermo Fisher Scientific), the cells were fixed using the Cytofix/Cytoperm kit (BD Biosciences) prior intracellular staining. Isotype and fluorescence minus one (FMO) controls were included. Doublets were discriminated using the FSC-H versus FSC-W strategy, and dead cells were discharged by staining with propidium iodide (PI) in fresh cell preparations, unless otherwise indicated, before acquisition on an LRS Fortessa X-20 cytometer (BD Biosciences). When indicated, cells were purified (over 95% purity) using a FACSAria-I (BD Biosciences) cell sorter. Cytometry data were analyzed using the FlowJo v10.8.1 (TreeStar, Ashland, OR, USA) and DIVA v8.0 (BD Biosciences) software packages. At least 1 × 105 live cells were analyzed in each sample and the cell populations were identified as indicated in Table S2. PE Annexin-V staining was performed following manufacturer’s instructions (Immunostep, Salamanca, Spain).
Gene expression analysis by RNA-Seq and computational data analysis
Total RNA was isolated from sorted FO, MZ and ABC using RNeasyⓇ kits (Qiagen, Hilden, Germany). Quantity and integrity of each RNA sample was checked using a Bioanalyzer at the CNIC Genomics Unit (Madrid, Spain). A total of 0.5 ng of RNA from MZ cells was used to generate barcoded RNA-seq libraries using the NEBNext Single Cell/Low Input RNA Library Prep Kit for Illumina (New England Biolabs, Ipswich, MA, USA) according to manufacturer’s instructions. First, cDNA strand synthesis was performed and then amplified by PCR followed by fragmentation. Next, cDNA ends were repaired and adenylated. The NEBNext adaptor was then ligated followed by second strand removal, uracil excision from the adaptor and PCR amplification. In the case of FO cells, 200 ng of total RNA were used to generate barcoded RNA-seq libraries using the NEBNext Ultra II Directional RNA Library Prep Kit (New England Biolabs). Poly A + RNA was purified using poly-T oligo-attached magnetic beads followed by fragmentation and then, first and second cDNA strand synthesis. Second strand was synthesized with U ribonucleotide instead of T. Next, cDNA 3' ends were adenylated and the adapters were ligated. Second strands were fragmented by USER enzyme that cuts the uracils to preserve the directionality of the original RNA. Once the libraries were generated, they were amplified by PCR. The size of the libraries was checked using the Agilent 2100 Bioanalyzer High Sensitivity DNA chip and their concentration was determined using the QubitⓇ fluorometer (Thermo Fisher Scientific). Libraries were sequenced on a HiSeq 4000 and processed with RTA v1.18.66.3. FastQ files for each sample were obtained using bcl2fastq v2.20.0.422 software (Illumina, San Diego, CA, USA). Sequencing reads were aligned to the mouse reference transcriptome (GRCm38 V90) and quantified with RSem v1.3.1 [43]. Raw counts were normalized with TPM (Transcripts per Million) and TMM (Trimmed Mean of M-values) methods, transformed into log2 expression (log2[rawCount + 1]) and compared to calculate fold-change and corrected P-value. Only those genes expressed with at least 1 count in a number of samples equal to the number of replicate samples of the condition with fewer replicates were considered. For functional analysis, those genes with |log2FC|> 0.58 and unadjusted P-value < 0.05 were considered, although we also calculated the Benjamini and Hochberg correction for all genes. Finally, heatmaps were generated with Morpheus online tool from Broad Institute (https://software.broadinstitute.org/morpheus), while pathway analysis and visualization of gene networks for each DEG list were performed using Ingenuity Pathway Analysis (Qiagen) and NetworkAnalyst [44] software, respectively.
RT-qPCR assays
Total RNA was extracted from purified FO, MZ, ABC B cells or from splenic B cell cultures using TRIsure™ (Bioline, London, UK) following the manufacturer’s instructions. Reverse-transcriptase polymerase chain reaction (RT-PCR) was performed using SuperscriptⓇ Vilo™ cDNA kit (Applied Biosystems™, Thermo Fisher Scientific). cDNA expression was evaluated by quantitative PCR (qPCR) performed in triplicates using TaqMan Fast-Advanced Master Mix (Applied Biosystems™, Thermo Fisher Scientific) in a CFX384 Real-Time System (BioRad, Hercules, CA, USA). The TaqMan assays used were: Mm99999915_g1 (Gapdh), Mm00446590_m1 (Tlr7), Mm00439531_m1 (Stat1), Mm00438023_m1 (Casp1), Mm01176201_mH (Zbtb44), Mm00510242_m1 (Mzb1), Mm01175819_m1 (Ets1), Mm00600614_m1 (Jak1), Mm00439544_m1 (Ifnar1), Mm00476128_m1 (Prdm1/Blimp1), Mm00457357_m1 (Xbp1) and Mm00507774_m1 (Aicd) (Thermo Fisher Scientific). For each sample, relative mRNA levels were determined using the comparative Ct (2-ΔΔCt) method (samples normalized to their Gapdh content).
Proliferation and differentiation analysis
Splenic cells were obtained after mechanical disaggregation of the spleen over a 40 μm cell strainer (FalconⓇ, Corning, NY, USA). Erythrocytes were removed by incubation with 1 mL of ACK lysis buffer for 2 min and washing twice in DPBS 1 X (Lonza Group). For B cell enrichment, cells were incubated with anti-Thy1.2 (clone J1J, in house reagent) for 20 min at room temperature (RT), washed to discard antibody excess and subsequently incubated with rabbit complement for 30 min at 37 °C (Cedarlane Laboratories), as described [45]. After T cell depletion, non-adherent cells were collected and washed. The recovered cells were enriched in B lymphocytes (> 95% CD19+). They were labelled with cell trace reagent (CellTracker™ BMQC Violet, Thermo Fisher Scientific), following the manufacturer’s instructions, and were seeded into flat-bottom 96-well culture plates (1 × 106 cells/mL). They were cultured for 6–96 h at 37 °C and 5% CO2 in complete RPMI 1640 (10% heat-inactivated FCS, 2 mM l-glutamine, 1 mM pyruvate, 50 mM 2-ME, 10 mM HEPES and antibiotics) in the presence of different stimuli: CL097 (2 μg/ml; InvivoGen, San Diego, CA, USA), Imiquimod/R837 (2 μg/ml; InvivoGen), IFNα (20 ng/ml; Biolegend, San Diego, CA, USA), LPS (25 μg/ml; Sigma-Aldrich, St. Louis, MO, USA) and anti-CD40 (10 μg/ml; HM40-3; eBioscience™, Thermo Fisher Scientific) with IL-4 (150 ng/ml; PeproTech, Thermo Fisher Scientific). Where indicated, the splenic B cell cultures were incubated with IFNα (20 ng/ml). Then, cells were washed with fresh cell medium and cultured for 6 h with the different stimuli. Proliferation was assessed by quantifying the cell trace dye-dilution representing cell divisions. B cell differentiation to plasma cells was studied by labeling with anti-CD138.
Cytokine analysis
Cytometric 13-multiplex cytokine bead arrays (CBA) were used to quantify IL-23, IL-1α, IFN-γ, TNF-α, CCL2 (MCP-1), IL-12p70, IL-1β, IL-10, IL-6, IL-27, IL-17A, IFN-β, GM-CSF (Biolegend) in culture samples. The determinations were performed in duplicate according to the manufacturer’s instructions. Samples were run on a CANTO I or FORTESSA (BD Biosciences) cytometer. The calibration curves were above r2 0.97.
Immunoglobulin (Ig) determination by ELISA
IgM, IgG and IgA were measured by ELISA in the supernatants obtained from B cell splenic cultures. Briefly, flat-bottom 96-well plates (Nunc, Rochester, NJ, USA) were coated with unlabeled goat-anti mouse total Ig (10 µg/ml; SouthernBiotech, Birmingham, AL, USA) and they were then blocked with 0.5% gelatin in phosphate buffered saline (PBS, BioWhittaker™, Lonza Group). Frozen supernatants were thawed and serial dilutions were prepared in the ELISA buffer (see below) and were plated in duplicate (at 50 μL/well). After overnight (4ºC) incubation, the plates were washed in PBS, 50 μL/well of biotinylated goat anti-mouse-IgM, -IgG or -IgA (SouthernBiotech) were added and the plates were incubated for 1 h. Subsequently, 50 μL/well of streptavidin-peroxidase (SouthernBiotech) were added and incubated for 30 min at RT. All the regents were previously tested and were diluted in 0.1% Tween-20 0.5% gelatin PBS. The ELISA plates were then revealed with 0.5 M O-phenylenediamine (Sigma-Aldrich) and the reaction was stopped with 3 N H2SO4. OD values were obtained at 450 nm in a Multiskan FC ELISA-reader (Thermo Fisher Scientific). Standard curves were generated using purified mouse IgM, IgG and IgA (SouthernBiotech), and the Ig concentrations were calculated using the GraphPad Prism 8.0 software.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 8.0 software after testing the normality of the data distributions with the Kolmogorov–Smirnov and D’Agostino-Pearson tests. The data are presented as the means ± SEM. Comparisons were performed using two-tailed unpaired Student's t-tests and ANOVA for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001.
Results
Tyk2 deficiency alters the number of MZ B cells and ABC
The splenic cellular content of Tyk2−/− mice exhibited similar relative and absolute numbers of B cells, NK cells, myeloid cells and T cells compared to control mice (Fig. 1A), although the distribution of B cell subsets was altered (Fig. 1B). Splenic B cell subpopulations [2] can be distinguished by the surface markers CD21 and CD23, into FO (CD21+CD23+), MZ (CD21++CD23lo/−) and ABC (CD21−CD23−), being ABC cells further identified on the basis of T-bet expression (Fig. 1B). In the absence of TYK2, FO B cells remained unchanged, MZ B cells were significantly decreased and ABC (T-bet+) were overrepresented (Fig. 1B). Cell quantification in peritoneal lavage, lymph nodes, Peyer’s patches and thymus showed no differences in B2, B1 or T cells (Fig. S1). To elucidate whether these differences were linked to defects in bone marrow precursors, we analyzed the B cell progenitor fractions as described [46] (Fig. 2A). No differences were found in any of the bone marrow B cell fractions in Tyk2−/− mice compared to controls. We then characterized transitional B cells in the spleen (T1, T2 and T3) on the basis of IgM and CD23 membrane expression of B220+CD93+ cells [47]. At 2 weeks of age, MZ B cells were not yet formed (Fig. 2C), and T1, T2 and T3 B cells were diminished in Tyk2−/− mice. This reduction was overcome at 4 weeks of age, when increased total numbers of T1 and T2 cells were observed (Fig. 2B), while similar numbers were maintained in older mice.
Since MZ B cells were not yet detected at 2 weeks of age (Fig. 2C) as described [48, 49], we performed PE Annexin-V studies on 4-week old juvenile mice [48, 50] to analyze whether apoptosis could explain the reduced numbers of MZ B cells. The results revealed that only FO, but not MZ B cells, had increased levels of apoptosis in Tyk2−/− mice (Fig. 2D). Furthermore, to rule out the possibility that MZ B cells were not being retained in the splenic niche, we analyzed their presence in peripheral blood. We observed that there were no MZ B cells in peripheral blood from either Tyk2−/− or WT mice discarding differences in migration of these cells (Fig. 2E).
All these results demonstrate that Tyk2 deficiency alters transitional B cell differentiation in juvenile mice and diminishes splenic MZ B cells without increased apoptosis or aberrant distribution of this population.
Differential gene expression analysis of isolated Tyk2−/− MZ and FO B cells shows a common inhibited type I IFN-dependent pathway
To search for candidate genes responsible for the impaired MZ B cell development in Tyk2−/− mice, we next compared the gene expression pattern of isolated MZ and FO B cells under homeostatic conditions by RNA-seq.
A total of 246 genes were differentially expressed compared to WT mice in Tyk2−/− MZ B cells vs the 78 found in Tyk2−/− FO B cells (Fig. 3, Tables S3 and S4). Among the differentially expressed genes (DEGs), 49 were shared by both types of B cells and were mainly related to type I IFN-signaling (Fig. 3C, D and Table S5). In addition, genes involved in necroptosis (Casp1, Irf9, Stat1 and Zbp1) and pyroptosis (Casp1, Casp4 and Tlr7) signaling pathways were also affected in MZ and FO B cells. Furthermore, in the case of MZ B cells most of the genes deregulated by Tyk2 deficiency corresponded to the EIF2 signaling pathway, which is involved in the stress-induced regulation of translation caused by viruses and bacteria [51, 52].
Tlr7 was also differentially expressed in FO and MZ B cells, linking Tyk2 deficiency with endosomal TLR7 sensing and response [53]. We validated these data by performing qPCRs (Fig. 4A) and found that Casp1, Stat1 and Tlr7 were significantly reduced in the three subpopulations of splenic Tyk2−/− B cells. By contrast, Zbtb44, which is a transcription factor that may be involved in hematopoiesis, oncogenesis and immune responses [54], did not reach significance in any case. In addition, we evaluated Mzb1 and Ets1, which are involved in plasma cell [55] and hematopoietic cell [56] differentiation, respectively. Their levels did not change in Tyk2−/− compared to WT B cells. Further, we analyzed intracellular TLR7 expression in FO, MZ and ABC by flow cytometry (Fig. 4B). There was a significant decrease of this receptor in MZ B cells of Tyk2−/− mice compared to those of WT mice, whereas non-significant differences were obtained for TLR7 expression in plasmacytoid dendritic cells (DC, data not shown). It has been described that TYK2 sustains the membrane expression of its associated receptor IFNAR1, although there is some controversy between studies in humans and mice [20, 57, 58]. We found by flow cytometry that IFNAR1 expression was lower in FO, MZ and ABC cells of Tyk2−/− mice compared to those of WT mice, although this difference did not reach statistical significance in the case of MZ B cells. The discrepancy with previous observations in B220+ splenic cells where no differences were detected [58] could be due to the B cell type-specific subpopulations analysed here.
We conclude that Tyk2 deficiency in splenic B cells is related to a defect in type I IFN signaling that affects the expression of TLR7 and IFNAR1.
Impaired proliferation and differentiation responses of Tyk2−/− splenic B cells to TLR7 ligands
To test whether the low expression of the Tlr7 gene in Tyk2−/− mice also entailed a deficient response to its ligands, we performed splenic B cell cultures in which T cells and monocytes had been depleted, in the presence of TLR7L (Imiquimod; IMIQ) and TLR7/TLR8L (CL097) for 72 h (Fig. 5). As positive controls, LPS and anti-CD40 + IL-4 were used to stimulate the innate TLR4-dependent and T cell-dependent responses, respectively. Given that TLR7 expression is induced by type I IFN [59], we added, where indicated, IFNα to splenic B cell cultures (Fig. 5B, D). The effect on proliferation was evaluated by a dye-dilution method after 72 h (Fig. 5A, B). WT B cells stimulated with IMIQ and CL097 showed higher proliferation than Tyk2−/− B cells, whereas no differences were observed when B cells were stimulated with LPS or anti-CD40 + IL-4. Plasmablast differentiation was studied by CD138 surface expression (Fig. 5C, D and Fig. S2). WT and Tyk2−/− B cells responded similarly to LPS and anti-CD40 + IL-4. In contrast, plasmablast differentiation in response to TLR7L was higher in WT as compared to Tyk2−/− B cells (Fig. 5D). Tyk2 deficiency was not associated with a lower B cell survival rate at 72 and 96 h of culture according to cell viability analysis with propidium iodide (data not shown).
IFNα significantly inhibited the proliferation of splenic B cells from WT compared to Tyk2−/− mice. Indeed, these latter were not inhibited compared to the Tyk2−/− unstimulated B cells (Figs. 5B and S2). These data are in agreement with those described in bone marrow-derived IL-7-stimulated adult B cells [40] and pro-B cells [41]. When IFNα was added to TLR7L, proliferation was upregulated both in WT and Tyk2−/− cultures with an additive response more noticeable with CL097 than with IMIQ (**P versus *P, Table S6). Intriguingly, the responses of WT and Tyk2−/− B cells were comparable (Fig. 5B and Table S6). The addition of IFNα to the different TLR7 agonists also led to greater plasmablast differentiation (Fig. 5D and Table S6), mostly in WT cultures, which presented higher CD138+ cell percentages than Tyk2−/− B cell cultures stimulated with IMIQ + IFNα. Therefore, there is an additive in vitro proliferative and differentiation response of IFNα with TLR7L, which is larger with CL097 than with IMIQ and partially compensates for the absence of TYK2.
Impaired TLR7 expression, cytokine and antibody secretion of Tyk2−/− splenic B cells in response to TLR7 ligands.
Since TLR7L-induced B cell differentiation was diminished in Tyk2−/− cells, we considered studying the expression of Tlr7 and several genes involved in antibody-producing cell formation. For this purpose, cells from the stimulated cultures were obtained and RNA was prepared to evaluate early (6 h) and late (48 h) gene response by qPCR (Fig. 6A and Fig. S3). Tlr7 expression was diminished in untreated Tyk2−/− compared to WT cells and was induced in response to all the treatments tested except for LPS in Tyk2−/− cells (Fig. 6A and Table S7). However, Tyk2−/− B cells failed to match the levels of WT B cells in response to the stimuli. According to these data, TLR7 protein expression (measured by intracellular flow cytometry) in gated FO, MZ and ABC developing in these cultures was also lower in Tyk2−/− compared to WT controls (Fig. 6B). Addition of TLR7 ligands alone did not induce Stat1 (Fig. S3). IFNα up-regulated Stat1 expression, both in WT and Tyk2−/− cells, although in the latter the induction was significantly lower. This difference was maintained in the presence of TLR7L + IFNα. Interestingly, Ifnar1 and Jak1 showed no changes in response to TLR7L or IFNα stimulation (Fig. S3). Of note, LPS scarcely induced Stat1 and Tlr7 expression in Tyk2−/−cells (see Fig. S3 and Fig. 6A), supporting the idea of a downregulated inflammation leading to the lack of sepsis described in Tyk2−/− mice in response to LPS [35, 36]. Regarding transcripts related to plasmablast differentiation such as B-lymphocyte-induced maturation protein-1 (Blimp1), X-Box Binding Protein 1 (Xbp1), or Activation-Induced Cytidine Deaminase (Aicd) genes [60–62], they were induced by TLR7L regardless of the presence or absence of IFN (Fig. S3).
Secreted cytokines were measured by cytometric bead array in the supernatants of splenic B cell cultures at 72 h (Fig. 6C). Of the 13 cytokines tested in the inflammation panel (see Material and methods), IL-6, IL-10 and TNF-α were detected in the supernatants. Production of IL-6 by B cells increases the pro-inflammatory status in response to infections or in autoimmune pathologies [63]. Furthermore, IL10-producing B cells are related with the presence of regulatory B cells (CD1d+CD5+), which may be present in the pool of splenic B cells used in the cultures [64]. We showed that IL-6 and IL-10 levels maintained a pattern that paralleled those observed in differentiation and proliferation under TLR7L stimulation. In particular, Tyk2−/− B cells produced lower levels of IL-6 compared to WT B cells in response to IMIQ and CL097. The addition of IFNα to CL097 had an additive effect in WT B cells, but this was not the case in Tyk2−/− cells (*P versus ns, Table S8). By contrast, no differences were detected in the other conditions tested (Fig. 6C). These effects were alike for the secretion of IL-10, whereas TNF-α production showed no differences in Tyk2−/− and WT B cells in response to TLR7L (Fig. 6C).
The secretion of IgM and class-switched IgA and IgG from cultured splenic B cells was assessed by ELISA after 96 h of culture with TLR7L (Fig. 6D). In response to LPS the Ig levels detected were similar. However, when stimulated with TLR7L, IgM and IgG, secretion was lower in Tyk2−/− B cells compared to controls. The IFNα had an additive effect with TLR7L, more evident with CL097 compared to IMIQ. This effect was observed both in WT and in Tyk2−/− B cells, although the latter secreted lower levels than WT B cells. Also, IgA levels were lower in Tyk2−/− B cells stimulated with CL097 and there was an additive response induced by the addition of IFNα in WT B cells. This effect was less evident in Tyk2−/− B cells, in which little or no IgA induction was observed relative to untreated B cells. Overall, the results showed that Tyk2−/− splenic B cells exhibited a diminished humoral response. From these results we conclude that Tyk2 deficiency decreases TLR7 expression and affects the responses through this receptor. This impaired TLR7 expression seems to be caused by a diminished type I IFN feedback loop and affects B cells.
Discussion
Type I IFNs are crucial in the antiviral response and modulation of the immune system. They act through IFNAR, which binds the cytoplasmic tyrosine kinases JAK1 and TYK2 initiating the IFN-I signaling pathway. TYK2 loss-of-function variants have been described as protective in the outcome of autoimmune diseases [25, 26]). Conversely, overexpression of TYK2 and certain proteins of its signaling pathway is associated with increased severity in the SARS-CoV-2 response [24].
Previously, our group reported in patients with B cell acute lymphoblastic leukemia TYK2 variants that impaired the response to IFNα in vitro [27]. Therefore, we sought to ascertain the effect of TYK2 deficiency on B cell populations in Tyk2−/− mice. Our results show that, while B cell populations in the bone marrow show no apparent alterations, in agreement with previous data [40, 41], splenic B cell populations exhibit remarkable changes under basal conditions, with a decrease of MZ B cells and an augmentation of ABC, while FO B cells remain unchanged. Previous analyses using the total number of splenic nucleated cells had overlooked these significant differences [41]. Other genetically modified mice in which MZ cells have been found to be decreased are Tlr8−/− and Tlr8/Tlr9−/− mice [65]. On the other hand, MZ B cell precursors (CD21hiIgMhiCD23hi) are increased in the autoimmune BXD2 mouse strain, which exhibits high levels of IFNα [66] underlining the central role of IFNα in the regulation of MZ B cells.
RNA-seq data comparing MZ and FO B cells from WT and Tyk2−/− mice under homeostatic conditions showed a signature of down-regulated IFN-I responsive genes that included programmed cell death genes, shared by MZ and FO B cells. TYK2 deficiency decreased gene expression related to inflammatory necroptosis and pyroptosis cell death signaling pathways in FO and MZ cells. In the last years, novel regulators such as the innate immune sensor Z-DNA binding protein (ZBP1) and the crosstalk between pyroptosis, apoptosis and necroptosis have been characterized [67]. IFN-I-mediated apoptosis in bone marrow-derived adult B cells and pro-B cells and the activation of CASP11-induced pyroptosis in mice is dependent on TYK2 [36, 40–42]. Our data also support the involvement of TYK2 in ZBP1, CASP1 and CASP4 regulation in splenic B cells, although the specific requirements and the understanding of these pathways deserve further investigation. In addition, there were also specific DEGs in each type of cell. In this regard, the canonical gene pathway that was most affected in MZ but not in FO B cells was EIF2 signaling [68]. The translation factor EIF2 is crucial for translation initiation and, therefore, reinforces the importance in MZ B cells of the type I IFN/TYK2 axis in protein synthesis and stress responses against viruses [69].
Pattern recognition receptors (PRRs) activate signaling cascades that lead to transcription of IFN-I, which triggers IFN-I responses through the IFNAR/JAK axis [70]. IFN-stimulated genes encode a network of intermediate proteins that modify the response by feedforward and feedback regulation of the IFN signaling pathway [71, 72]. We observed that under homeostasis, in the absence of TYK2, poor IFNα-stimulated gene expression was detected in MZ and FO B cells and, among PRRs, only Tlr7 was identified as a DEG. In consequence, Tyk2−/− B cell splenic cultures showed weak proliferation and differentiation in response to TLR7L, while the response to TLR4 ligand or anti-CD40 + IL-4 was similar to that of WT B cells. Addition of IFNα to the cultures, alone or plus TLR7L, induced TLR7 expression. These data support previous reports on induction of TLR7 expression in B cells [73, 74], although in our case the low basal TLR7 expression in Tyk2−/− splenic B cells precluded reaching WT expression after B cell stimulation, both at the RNA and protein level. These lower TLR7 levels seem to be enough to trigger normal B cell proliferation, suggesting a complete activation of the IFNAR/JAK axis via JAK1 signaling [29, 75]. However, neither the differentiation nor the humoral response matched that of WT B cells, even in the presence of IFNα plus TLR7L. Therefore, TYK2 seems to specifically mediate the complete differentiation to antibody-producing cells mediating Ig and cytokine responses.
In vitro B cell stimulation with anti-CD40 + IL-4 mimics the stimulation triggered by the interaction of FO B cells with T follicular helper (Tfh) cells through the BCR, promoting B cell differentiation and humoral responses [45, 76]. In our model, splenic Tyk2−/− B cells did not release IL-6, IL-10 or TNF-α in response to anti-CD40 + IL-4. In addition, although upregulated IgM production was detected in Tyk2−/− B cells compared to WT cells, no differences were observed in IgG or IgA secretion. In humans with TYK2 loss-of-function mutations, polarization toward Th2 cytokine production increases in memory CD4+ T cells, whereas Th17 cytokines and IL-10 secretion decreases [26, 39]. The generation of memory B cells is not affected in these patients, while there is a trend for more switched memory B cells [39]. However, healthy individuals homozygous for the protective autoimmune TYK2 P1104A variant exhibit a decrease in both Tfh cells and switched memory B cells [26]. However, studies on a murine model homozygous for TYK2 P1104A showed no impact on Tfh and germinal center B cell formation following T-dependent immunization [26]. Further investigation of T-dependent responses in Tyk2−/− mice will elucidate whether germinal center reaction is affected by TYK2 deficiency.
In addition to TLR7, other IFN-regulated TLRs have been described (i.e., TLR1, TLR3, TLR5 and TLR8) [77]. The IFN-regulated TLRs exhibit enrichment of conserved IFN-responsive elements (ISRE) and STAT1 sites on their promoters. Interestingly, the TLR7 promoter has four putative conserved sites for STAT1 [78] suggesting a fine tuning of TLR7 expression by this transcription factor. Consistent with this, we have found that Stat1 is the only member of the STAT family differentially downregulated in Tyk2−/− MZ and FO B cells. These data agree with the low STAT1 expression found in bone marrow-derived macrophages of Tyk2−/− mice [28] and support the proposed role for STAT1 in MZ B cell differentiation [79]. Therefore, STAT1 seems to be a mediator in the crosstalk between TYK2 and TLR7 in activated cells, although the involvement of other genes cannot be ruled out (Fig. 7A). We propose that, in Tyk2−/− MZ and FO B cells, the tonic signal proposed to be induced by constitutive type I IFN without stimulus [71] is very low, if exists, thereby precluding the TLR7 activation necessary for optimal differentiation and proliferation (Fig. 7B).
Our data reveal that TYK2 has an impact on TLR7 expression and function, and this crosstalk is mediated by type I IFN signaling. The activation of this gene network influences B cell distribution, the differentiation and the establishment of MZ B cells as well as the production of cytokines and Igs. In addition, this mechanism may explain the greater susceptibility to viruses and encapsulated bacteria found in Tyk2-deficient patients [19–21, 23], and in Tyk2−/− mice [28]. Furthermore, Tyk2 deficiency protects mice from severe inflammation in Systemic Lupus Erythematosus (SLE), arthritis and psoriasis [31, 33, 34]. In fact, a tight control and regulation of TLR7 is pivotal for avoiding SLE and inflammatory pathology in mice [65]. Therefore, we provide compelling evidence that TLR7 is a specific target of a TYK2 orchestrated IFN-I mediated feedback loop in B cells. Consequently, the possible therapeutic use of TYK2 inhibitors in autoimmune diseases should take into account their impact on TLR7 expression, which may lead to a low antiviral response in these patients. Similarly, the use of TLR7-activating adjuvants in viral vaccines may be useful for patients with TYK2 loss-of-function variants.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
We thank the personnel of the Genomics Unit of the CNIC for RNA sequencing; Dr. Rodrigo Jiménez-Saiz for helpful discussion and critical reading of the manuscript; Dr. José María Serra for providing resources; Dr. Manuel Gómez (IIS-Princesa) for editing the manuscript and the Fundación de Investigación Biomédica (FIB) administrative staff for support.
Abbreviations
- TYK2
Tyrosine kinase 2
- Tyk2−/−
TYK2-deficient mice
- ABC
Aged B cells
- MZ
Marginal zone
- FO
Follicular
- TLR7
Toll-like receptor 7
- TLR7L
Toll-like receptor 7 ligands
- IFN-I
Type I interferon
- IFNAR
IFN α/β receptor
- DEG
Differentially expressed gene
- WT
Wild type
- Igs
Immunoglobulins
- LPS
Lipopolysaccharide
Author contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Irene Bodega-Mayor, Pablo Delgado Wicke, Alejandro Arrabal, Estíbaliz Alegría-Carrasco, Ana Nicolao-Gómez and Marta Jaén-Castaño. Transcriptomic experiments and analysis: Cristina Espadas, Ana Dopazo and Enrique Martín-Gayo. The first draft of the manuscript was written by Elena Fernández-Ruiz and Belén de Andrés, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Funding
This study was supported by Instituto de Salud Carlos III from the Spanish Ministry of Science and Innovation, and the European Regional Development Fund (ISCIII-FEDER) “A way to achieve Europe”, Grants PI19/00096 and PI22/00428 to EF-R and PID2022-1417540B-I00 for BdA and MLG. PDW and AA were supported by PI19/00096, EAC and ANG by INVESTIGO (Exp. 2022-C23.I01.P03.S0020-0000031) and INVESTIGO CAM (Exp. 09-PIN1-00015.6/2022) from the Spanish Ministry of Science and Innovation and Comunidad Autónoma de Madrid, respectively, both financed by the European Union’s Recovery, Transformation and Resilience Plan and NextGenerationEU, and MJC was supported by Dirección General de Innovación e Investigación Tecnológica de la Comunidad de Madrid (RETARACOVID, Grant P2022/BMD-7274 to EF-R).
Data availability
The datasets generated during the current study are included in the Supplementary Material. Further inquiries can be directed to the corresponding author.
Declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Ethical approval
Mice were bred and maintained in the animal facilities at the School of Medicine of the Universidad Autónoma de Madrid. All experiments were performed in accordance with the National RD 53/2013 and European Union 2010/63/EU directive and under the EU and National Animal Care guidelines. All protocols were approved by Consejería de Medio Ambiente de la Comunidad de Madrid (PROEX 353.8/21).
Consent to participate
Not applicable.
Consent to publish
Not applicable.
Footnotes
The original online version of this article was revised to include the missing author name Enrique Vázquez de Luis and update the error in the figure 3 and supplement table s3.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Irene Bodega-Mayor and Pablo Delgado-Wicke contributed equally to this work and share first authorship.
Belén de Andrés and Elena Fernández-Ruiz contributed equally to this work and share senior authorship.
Change history
11/14/2024
The article has been updated to include the missing author name Enrique Vázquez de Luis and update the error in the figure 3 and supplement table s3.
Change history
11/15/2024
A Correction to this paper has been published: 10.1007/s00018-024-05482-y
References
- 1.Smith FL, Baumgarth N (2019) B-1 cell responses to infections. Curr Opin Immunol 57:23–31. 10.1016/j.coi.2018.12.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.LeBien TW, Tedder TF (2008) B lymphocytes: how they develop and function. Blood 112:1570–1580. 10.1182/blood-2008-02-078071 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Nickerson KM, Smita S, Hoehn KB et al (2023) Age-associated B cells are heterogeneous and dynamic drivers of autoimmunity in mice. J Exp Med 220:e20221346. 10.1084/jem.20221346 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Victora GD, Nussenzweig MC (2012) Germinal Centers. Annu Rev Immunol 30:429–457. 10.1146/annurev-immunol-020711-075032 [DOI] [PubMed] [Google Scholar]
- 5.Martin F, Oliver AM, Kearney JF (2001) Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 14:617–629. 10.1016/s1074-7613(01)00129-7 [DOI] [PubMed] [Google Scholar]
- 6.Srivastava B, Quinn WJ, Hazard K et al (2005) Characterization of marginal zone B cell precursors. J Exp Med 202:1225–1234. 10.1084/jem.20051038 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity by the innate immune system. Science 327:291–295. 10.1126/science.1183021 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Meyer-Bahlburg A, Rawlings DJ (2012) Differential impact of Toll-like receptor signaling on distinct B cell subpopulations. Front Biosci 17:1499–1516. 10.2741/4000 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Glaum MC, Narula S, Song D et al (2009) Toll-like receptor 7–induced naive human B-cell differentiation and immunoglobulin production. J Allergy Clin Immunol 123:224-230.e4. 10.1016/j.jaci.2008.09.018 [DOI] [PubMed] [Google Scholar]
- 10.Stark GR, Darnell JE (2012) The JAK-STAT pathway at twenty. Immunity 36:503–514. 10.1016/j.immuni.2012.03.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Velazquez L, Fellous M, Stark GR, Pellegrini S (1992) A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70:313–322. 10.1016/0092-8674(92)90105-l [DOI] [PubMed] [Google Scholar]
- 12.Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375–386. 10.1038/nri1604 [DOI] [PubMed] [Google Scholar]
- 13.Levy DE, Kessler DS, Pine R et al (1988) Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev 2:383–393. 10.1101/gad.2.4.383 [DOI] [PubMed] [Google Scholar]
- 14.Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14:36–49. 10.1038/nri3581 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Stark GR, Kerr IM, Williams BR et al (1998) How cells respond to interferons. Annu Rev Biochem 67:227–264. 10.1146/annurev.biochem.67.1.227 [DOI] [PubMed] [Google Scholar]
- 16.van Boxel-Dezaire AHH, Rani MRS, Stark GR (2006) Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25:361–372. 10.1016/j.immuni.2006.08.014 [DOI] [PubMed] [Google Scholar]
- 17.Strobl B, Stoiber D, Sexl V, Mueller M (2011) Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front Biosci 16:3214–3232. 10.2741/3908 [DOI] [PubMed] [Google Scholar]
- 18.Hammarén HM, Virtanen AT, Raivola J, Silvennoinen O (2019) The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine 118:48–63. 10.1016/j.cyto.2018.03.041 [DOI] [PubMed] [Google Scholar]
- 19.Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S et al (2012) A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr 160:1055–1057. 10.1016/j.jpeds.2012.01.056 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Kreins AY, Ciancanelli MJ, Okada S et al (2015) Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med 212:1641–1662. 10.1084/jem.20140280 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Minegishi Y, Saito M, Morio T et al (2006) Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25:745–755. 10.1016/j.immuni.2006.09.009 [DOI] [PubMed] [Google Scholar]
- 22.Nemoto M, Hattori H, Maeda N et al (2018) Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia. Sci Rep 8:6956. 10.1038/s41598-018-25260-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Ogishi M, Arias AA, Yang R et al (2022) Impaired IL-23-dependent induction of IFN-γ underlies mycobacterial disease in patients with inherited TYK2 deficiency. J Exp Med 219:e20220094. 10.1084/jem.20220094 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Pairo-Castineira E, Clohisey S, Klaric L et al (2021) Genetic mechanisms of critical illness in COVID-19. Nature 591:92–98. 10.1038/s41586-020-03065-y [DOI] [PubMed] [Google Scholar]
- 25.Dendrou CA, Cortes A, Shipman L et al (2016) Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 10.1126/scitranslmed.aag1974 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Gorman JA, Hundhausen C, Kinsman M et al (2019) The TYK2-P1104A autoimmune protective variant limits coordinate signals required to generate specialized T cell subsets. Front Immunol 10:44. 10.3389/fimmu.2019.00044 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Turrubiartes-Martínez E, Bodega-Mayor I, Delgado-Wicke P et al (2020) TYK2 variants in B-Acute lymphoblastic leukaemia. Genes 11:1434. 10.3390/genes11121434 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Karaghiosoff M, Neubauer H, Lassnig C et al (2000) Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13:549–560. 10.1016/s1074-7613(00)00054-6 [DOI] [PubMed] [Google Scholar]
- 29.Shimoda K, Kato K, Aoki K et al (2000) Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 13:561–571. 10.1016/s1074-7613(00)00055-8 [DOI] [PubMed] [Google Scholar]
- 30.Shimoda K, Tsutsui H, Aoki K et al (2002) Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood 99:2094–2099. 10.1182/blood.v99.6.2094 [DOI] [PubMed] [Google Scholar]
- 31.Ishizaki M, Akimoto T, Muromoto R et al (2011) Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Immunol 187:181–189. 10.4049/jimmunol.1003244 [DOI] [PubMed] [Google Scholar]
- 32.Oyamada A, Ikebe H, Itsumi M et al (2009) Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J Immunol 183:7539–7546. 10.4049/jimmunol.0902740 [DOI] [PubMed] [Google Scholar]
- 33.Ishizaki M, Muromoto R, Akimoto T et al (2011) Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Int Immunol 23:575–582. 10.1093/intimm/dxr057 [DOI] [PubMed] [Google Scholar]
- 34.Ishizaki M, Muromoto R, Akimoto T et al (2014) Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol 26:257–267. 10.1093/intimm/dxt062 [DOI] [PubMed] [Google Scholar]
- 35.Karaghiosoff M, Steinborn R, Kovarik P et al (2003) Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 4:471–477. 10.1038/ni910 [DOI] [PubMed] [Google Scholar]
- 36.Poelzl A, Lassnig C, Tangermann S et al (2021) TYK2 licenses non-canonical inflammasome activation during endotoxemia. Cell Death Differ 28:748–763. 10.1038/s41418-020-00621-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Bosmann M, Strobl B, Kichler N et al (2014) Tyrosine kinase 2 promotes sepsis-associated lethality by facilitating production of interleukin-27. J Leukoc Biol 96:123–131. 10.1189/jlb.3A1013-541R [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Hirashima K, Muromoto R, Minoguchi H et al (2020) The mechanism of Tyk2 deficiency-induced immunosuppression in mice involves robust IL-10 production in macrophages. Cytokine 130:155077. 10.1016/j.cyto.2020.155077 [DOI] [PubMed] [Google Scholar]
- 39.Ma CS, Wong N, Rao G et al (2015) Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies. J Allergy Clin Immunol 136:993-1006.e1. 10.1016/j.jaci.2015.05.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Shimoda K, Kamesaki K, Numata A et al (2002) Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation. J Immunol 169:4707–4711. 10.4049/jimmunol.169.9.4707 [DOI] [PubMed] [Google Scholar]
- 41.Gamero AM, Potla R, Wegrzyn J et al (2006) Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells. J Biol Chem 281:16238–16244. 10.1074/jbc.M509516200 [DOI] [PubMed] [Google Scholar]
- 42.Potla R, Koeck T, Wegrzyn J et al (2006) Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Mol Cell Biol 26:8562–8571. 10.1128/MCB.00497-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Li B, Dewey CN (2011) RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12:323. 10.1186/1471-2105-12-323 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Zhou G, Soufan O, Ewald J et al (2019) NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res 47:W234–W241. 10.1093/nar/gkz240 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.de Andrés B, Prado C, Palacios B et al (2012) Dynamics of the splenic innate-like CD19+CD45Rlo cell population from adult mice in homeostatic and activated conditions. J Immunol 189:2300–2308. 10.4049/jimmunol.1200224 [DOI] [PubMed] [Google Scholar]
- 46.Hardy RR, Carmack CE, Shinton SA et al (2012) Pillars article: resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 1991 189:3271–3283 [PubMed] [Google Scholar]
- 47.Allman D, Pillai S (2008) Peripheral B cell subsets. Curr Opin Immunol 20:149–157. 10.1016/j.coi.2008.03.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Martin F, Kearney JF (2002) Marginal-zone B cells. Nat Rev Immunol 2:323–335. 10.1038/nri799 [DOI] [PubMed] [Google Scholar]
- 49.Lortan J, Gray D, Kumararatne DS et al (1985) Regulation of the size of the recirculating B cell pool of adult rats. Adv Exp Med Biol 186:593–601. 10.1007/978-1-4613-2463-8_72 [DOI] [PubMed] [Google Scholar]
- 50.MacLennan IC, Bazin H, Chassoux D et al (1985) Comparative analysis of the development of B cells in marginal zones and follicles. Adv Exp Med Biol 186:139–144. 10.1007/978-1-4613-2463-8_17 [DOI] [PubMed] [Google Scholar]
- 51.García MA, Meurs EF, Esteban M (2007) The dsRNA protein kinase PKR: virus and cell control. Biochimie 89:799–811. 10.1016/j.biochi.2007.03.001 [DOI] [PubMed] [Google Scholar]
- 52.Hsu L-C, Park JM, Zhang K et al (2004) The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 428:341–345. 10.1038/nature02405 [DOI] [PubMed] [Google Scholar]
- 53.Diebold SS, Kaisho T, Hemmi H et al (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529–1531. 10.1126/science.1093616 [DOI] [PubMed] [Google Scholar]
- 54.Zhu C, Chen G, Zhao Y et al (2018) Regulation of the development and function of B cells by ZBTB transcription factors. Front Immunol 9:580. 10.3389/fimmu.2018.00580 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Andreani V, Ramamoorthy S, Pandey A et al (2018) Cochaperone Mzb1 is a key effector of Blimp1 in plasma cell differentiation and β1-integrin function. Proc Natl Acad Sci. 10.1073/pnas.1809739115 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Dittmer J (2003) The biology of the Ets1 proto-oncogene. Mol Cancer 2:29. 10.1186/1476-4598-2-29 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Ragimbeau J, Dondi E, Alcover A et al (2003) The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J 22:537–547. 10.1093/emboj/cdg038 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Sheehan KCF, Lai KS, Dunn GP et al (2006) Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res 26:804–819. 10.1089/jir.2006.26.804 [DOI] [PubMed] [Google Scholar]
- 59.Bekeredjian-Ding IB, Wagner M, Hornung V et al (2005) Plasmacytoid dendritic cells control TLR7 sensitivity of naive B Cells via type I IFN. J Immunol 174:4043–4050. 10.4049/jimmunol.174.7.4043 [DOI] [PubMed] [Google Scholar]
- 60.Nadeau S, Martins GA (2021) Conserved and unique functions of Blimp1 in immune cells. Front Immunol 12:805260. 10.3389/fimmu.2021.805260 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Reimold AM, Iwakoshi NN, Manis J et al (2001) Plasma cell differentiation requires the transcription factor XBP-1. Nature 412:300–307. 10.1038/35085509 [DOI] [PubMed] [Google Scholar]
- 62.Shinkura R, Ito S, Begum NA et al (2004) Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat Immunol 5:707–712. 10.1038/ni1086 [DOI] [PubMed] [Google Scholar]
- 63.Kishimoto T (2010) IL-6: from its discovery to clinical applications. Int Immunol 22:347–352. 10.1093/intimm/dxq030 [DOI] [PubMed] [Google Scholar]
- 64.Maseda D, Smith SH, DiLillo DJ et al (2012) Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo. J Immunol 188:1036–1048. 10.4049/jimmunol.1102500 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Desnues B, Macedo AB, Roussel-Queval A et al (2014) TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice. Proc Natl Acad Sci 111:1497–1502. 10.1073/pnas.1314121111 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Wang JH, Li J, Wu Q et al (2010) Marginal zone precursor B cells as cellular agents for type I IFN-promoted antigen transport in autoimmunity. J Immunol 184:442–451. 10.4049/jimmunol.0900870 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Malireddi RKS, Kesavardhana S, Kanneganti T-D (2019) ZBP1 and TAK1: Master regulators of NLRP3 inflammasome/pyroptosis, apoptosis, and necroptosis (PAN-optosis). Front Cell Infect Microbiol 9:406. 10.3389/fcimb.2019.00406 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Adomavicius T, Guaita M, Zhou Y et al (2019) The structural basis of translational control by eIF2 phosphorylation. Nat Commun 10:2136. 10.1038/s41467-019-10167-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Schoof M, Wang L, Cogan JZ et al (2021) Viral evasion of the integrated stress response through antagonism of eIF2-P binding to eIF2B. Nat Commun 12:7103. 10.1038/s41467-021-26164-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Mogensen TH (2009) Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22:240–273. 10.1128/CMR.00046-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Gough DJ, Messina NL, Clarke CJP et al (2012) Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36:166–174. 10.1016/j.immuni.2012.01.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Michalska A, Blaszczyk K, Wesoly J, Bluyssen HAR (2018) A positive feedback amplifier circuit that regulates interferon (IFN)-stimulated gene expression and controls type I and type II IFN responses. Front Immunol 9:1135. 10.3389/fimmu.2018.01135 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Green NM, Laws A, Kiefer K et al (2009) Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J Immunol 183:1569–1576. 10.4049/jimmunol.0803899 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Genestier L, Taillardet M, Mondiere P et al (2007) TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol 178:7779–7786. 10.4049/jimmunol.178.12.7779 [DOI] [PubMed] [Google Scholar]
- 75.Müller M, Briscoe J, Laxton C et al (1993) The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 366:129–135. 10.1038/366129a0 [DOI] [PubMed] [Google Scholar]
- 76.Papa I, Vinuesa CG (2018) Synaptic interactions in germinal centers. Front Immunol 9:1858. 10.3389/fimmu.2018.01858 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ (2009) Interferome: the database of interferon regulated genes. Nucleic Acids Res 37:D852-857. 10.1093/nar/gkn732 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Khoo JJ, Forster S, Mansell A (2011) Toll-like receptors as interferon-regulated genes and their role in disease. J Interferon Cytokine Res 31:13–25. 10.1089/jir.2010.0095 [DOI] [PubMed] [Google Scholar]
- 79.Chen T-T, Tsai M-H, Kung JT et al (2016) STAT1 regulates marginal zone B cell differentiation in response to inflammation and infection with blood-borne bacteria. J Exp Med 213:3025–3039. 10.1084/jem.20151620 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The datasets generated during the current study are included in the Supplementary Material. Further inquiries can be directed to the corresponding author.